bluebird bio, Inc. - Common Stock (NQ:BLUE)

Long-term Follow-up Data From bluebird’s Gene Therapy Program in Sickle Cell Disease Support Durable, Potentially Curative Benefits Through Stable Production of Anti-Sickling Adult Hemoglobin and Resolution of Vaso-Occlusive Events

December 09, 2023

FDA Approves First Gene-Editing Cell Therapy For Sickle Cell Disease, An Inherited Blood Disorder ↗

December 08, 2023

The FDA has approved Casgevy and Lyfgenia, representing the first cell-based gene therapies for sickle cell disease in patients 12 y

Via Benzinga

What's Going On With Bluebird Bio Stock? ↗

December 08, 2023

Bluebird Bio, Inc.

Via Benzinga

2 Biotech Stocks That Could Soar in December ↗

November 26, 2023

These two biotechs have important catalysts coming up in December.

This biotech looks cheap, but is it a value trap?

Is Bluebird Bio Stock a Buy? ↗

November 04, 2023

bluebird bio Details Plans for the Commercial Launch of LYFGENIA™ Gene Therapy for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events

December 08, 2023

bluebird bio Announces FDA Approval of LYFGENIA™ (lovotibeglogene autotemcel) for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events

December 08, 2023

Torrid Reports Upbeat Results, Joins MBIA, Virco Mfg. And Other Big Stocks Moving Higher On Friday ↗

December 08, 2023

U.S. stocks traded mostly higher, with the Dow Jones index gaining more than 40 points on Friday.

Via Benzinga

Topics Stocks

Where Will Bluebird Bio Be in 1 Year? ↗

September 29, 2023

Things could get better for the biotech, but they could also get worse.

One thing is for certain -- both of these companies are innovators.

These 2 Stocks Could Be About to Soar: Are They Buys? ↗

December 07, 2023

As we head into December 2023, some of the hottest investment opportunities can be found in these biotech stocks.

If You Can Only Buy One Biotech Stock in December, It Better Be One of These 3 Names ↗

November 29, 2023

Via InvestorPlace

Why FLJ Group Shares Are Trading Higher By Around 96%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

November 24, 2023

Shares of FLJ Group Limited (NASDAQ: FLJ) shares jumped during Friday’s session after the company announced it entered into a definitive agreement to acquire Alpha Mind Technology. FLJ Group shares...

Via Benzinga

2 Beaten-Down Growth Stocks That Could Rocket 42% to 67% Higher, According to Wall Street ↗

November 20, 2023

Investment bank analysts are pounding the table on these stocks, but are they right for your portfolio?

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page

Bluebird Bio To Rally Around 267%? Here Are 10 Top Analyst Forecasts For Wednesday ↗

November 08, 2023

Via Benzinga

Why Bluebird Bio Stock Soared 7% Higher on Tuesday ↗

November 07, 2023

The company posted some encouraging numbers and said it had sufficient resources to take care of financial obligations through the second quarter of 2024.

bluebird bio Reports Third Quarter 2023 Financial Results and Highlights Operational Progress

November 07, 2023

bluebird bio to Present New and Updated Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition

November 02, 2023

Gene Therapy Could Be On the Cusp of a Major Breakthrough, but Investors May Have to Remain Patient ↗

October 30, 2023

This gene-editing pioneer could make history this week. But shareholders should remain focused on the long term.

bluebird bio Enters into Advance Agreement to Sell Priority Review Voucher, if Granted, for $103 Million

October 30, 2023

bluebird bio to Host Third Quarter 2023 Financial Results Conference Call

October 24, 2023

Cautious Optimism For Bluebird Bio's Sickle Cell Therapy: Analyst Sees Financial Challenges ↗

October 17, 2023

Cantor Fitzgerald initiated coverage on Bluebird Bio Inc (NASDAQ: BLUE), saying sickle cell disorder (SCD) has been a hotbed of development for genetic medicines as the company's lovo-cel marches...

Via Benzinga

Editas Medicine Has To Navigate Sickle Cell Therapy Competition: Analyst ↗

October 17, 2023

Cantor Fitzgerald has downgraded Editas Medicine Inc (NASDAQ: EDIT) to Neutral from Overw

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 17, 2023 ↗

October 17, 2023

Via Benzinga

Cathie Wood Is Buying This Growth Stock Hand Over Fist Lately. Should You Follow Her Lead? ↗

October 03, 2023

The Internet's most famous innovation-focused investor is excited about this company's innovative approach to editing the human genome.

Fisker, Intercept Pharmaceuticals, Immunovant And Other Big Stocks Moving Higher On Tuesday ↗

September 26, 2023

U.S. stocks traded lower, with the Dow Jones falling around 200 points on Tuesday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Topics Stocks

Are Gene Therapy Stocks The Market's Next Big Winners?

September 25, 2023

Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price.

Via MarketBeat

Topics Artificial Intelligence

Better Growth Stock: CRISPR Therapeutics vs. Bluebird Bio ↗

September 20, 2023

These two biotechs have a lot in common, but one is much better capitalized.

Good medicines aren't always good business.

1 Huge Risk That Gene-Editing Stock Investors Desperately Need to Know ↗

September 19, 2023